

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

SOARES, Christopher J.

**Appln. No.:** 10/589,054

**Filing/371(c)** April 1, 2008

**Date:**

**Title:** *Amylin Family Peptides and Methods for  
Making and Using Them*

**Art Unit:** 1646

**Examiner:** Howard, Zachary C.

**Atty. Docket:** 0105US-UTL2

**Confirm. No.:** 5466

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

In compliance with 37 C.F.R. §1.56, the patent document listed on the attached Form PTO/SB/08B is being submitted herewith for consideration by the Examiner. In accordance with 37 C.F.R. 1.98, a copy of each of the listed items, other than U.S. Patents and U.S. Patent Application Publications, is included herewith. Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08B, indicating that the information has been considered and made of record herein.

The listed references are being cited only in the interests of candor and without any admission that they constitutes statutory prior art or contains matter which anticipates the invention or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art.


No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual

designated in § 1.56(c) more than three months prior to the filing of this information disclosure statement.

Applicant believes no fees are due with this submission. If Applicant is in error, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 01-0535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,  
AMYLIN PHARMACEUTICALS, INC.

Dated: September 22, 2010

  
Belinda M. Lew  
Registration No. 53,212

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858.552.2200  
Facsimile: 858.552.1936